Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry J Copeland

Showing results (41-50 of 103) with videos related to

Pageof 11
Sort By:
Gynecologic Oncology|October 5, 2018
Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer CenterAdam C ElNaggar, Erinn M Hade, David M O'Malley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 14, 2015
The Use of Transvaginal Ultrasound in Type II Endometrial CancerCaroline C Billingsley, Kimberly A Kenne, Catherine D Cansino, et al.
Gynecologic Oncology|June 12, 2009
Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancerFloor J Backes, Marino E Leon, Iouri Ivanov, et al.
Gynecologic Oncology|August 30, 2025
The price of delay: Insurance-related treatment delays in patients with gynecologic cancer receiving immunotherapyMolly Morton, Julia Chalif, Jessica Sciuva, et al.
AJOG Global Reports|October 24, 2022
Wound complications following vulvar excision for nonmalignant lesionsGlenn P Boyles, Ashlee M Weaver, David E Cohn, et al.
Familial Cancer|July 31, 2009
Are prediction models for Lynch syndrome valid for probands with endometrial cancer?Floor J Backes, Heather Hampel, Katherine A Backes, et al.
Gynecologic Oncology|July 29, 2015
Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer CenterMargaret I Liang, Adam C ElNaggar, Silpa Nekkanti, et al.
American Journal of Obstetrics and Gynecology|August 12, 2019
Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasiaMonica Hagan Vetter, Blair Smith, Jason Benedict, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 4, 2013
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?Floor J Backes, Debra L Richardson, Georgia A McCann, et al.
Gynecologic Oncology|February 6, 2019
Conization pathologic features as a predictor of intermediate and high risk features on radical hysterectomy specimens in early stage cervical cancerMegan L Hutchcraft, Blair Smith, Eric M McLaughlin, et al.
Pageof 11

Showing results (41-50 of 103) with videos related to

Sort By:
Pageof 11
Gynecologic Oncology|October 5, 2018
Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer CenterAdam C ElNaggar, Erinn M Hade, David M O'Malley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 14, 2015
The Use of Transvaginal Ultrasound in Type II Endometrial CancerCaroline C Billingsley, Kimberly A Kenne, Catherine D Cansino, et al.
Gynecologic Oncology|June 12, 2009
Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancerFloor J Backes, Marino E Leon, Iouri Ivanov, et al.
Gynecologic Oncology|August 30, 2025
The price of delay: Insurance-related treatment delays in patients with gynecologic cancer receiving immunotherapyMolly Morton, Julia Chalif, Jessica Sciuva, et al.
AJOG Global Reports|October 24, 2022
Wound complications following vulvar excision for nonmalignant lesionsGlenn P Boyles, Ashlee M Weaver, David E Cohn, et al.
Familial Cancer|July 31, 2009
Are prediction models for Lynch syndrome valid for probands with endometrial cancer?Floor J Backes, Heather Hampel, Katherine A Backes, et al.
Gynecologic Oncology|July 29, 2015
Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer CenterMargaret I Liang, Adam C ElNaggar, Silpa Nekkanti, et al.
American Journal of Obstetrics and Gynecology|August 12, 2019
Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasiaMonica Hagan Vetter, Blair Smith, Jason Benedict, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 4, 2013
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?Floor J Backes, Debra L Richardson, Georgia A McCann, et al.
Gynecologic Oncology|February 6, 2019
Conization pathologic features as a predictor of intermediate and high risk features on radical hysterectomy specimens in early stage cervical cancerMegan L Hutchcraft, Blair Smith, Eric M McLaughlin, et al.
Pageof 11